BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 29935898)

  • 21. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carfilzomib: a novel second-generation proteasome inhibitor.
    Khan ML; Stewart AK
    Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
    Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
    Driscoll JJ; Burris J; Annunziata CM
    Am J Ther; 2012 Mar; 19(2):133-44. PubMed ID: 21248621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication use evaluation of the financial and clinical implications of ixazomib compared to bortezomib in the outpatient setting.
    Zink KA; Fajardo S
    J Oncol Pharm Pract; 2021 Mar; 27(2):279-282. PubMed ID: 32279598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New approaches to management of multiple myeloma.
    Genadieva-Stavric S; Cavallo F; Palumbo A
    Curr Treat Options Oncol; 2014 Jun; 15(2):157-70. PubMed ID: 24578203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
    Hall KH
    Oncology (Williston Park); 2019 Mar; 33(3):89-90. PubMed ID: 30866030
    [No Abstract]   [Full Text] [Related]  

  • 38. Ixazomib - the first oral proteasome inhibitor.
    Xie J; Wan N; Liang Z; Zhang T; Jiang J
    Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
    Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral therapy for multiple myeloma: ixazomib arriving soon.
    Moreau P
    Blood; 2014 Aug; 124(7):986-7. PubMed ID: 25124778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.